Drug evaluation: DNA/MVA prime-boost HIV vaccine.
Curr Opin Investig Drugs
; 8(2): 159-67, 2007 Feb.
Article
em En
| MEDLINE
| ID: mdl-17328232
ABSTRACT
Oxford University and Nairobi University are jointly developing a HIVA.DNA/modified vaccinia Ankara (MVA) prime-boost vaccine for the potential prevention of infection with HIV subtype A. The vaccination strategy consists of priming with a DNA vaccine made from HIV-1 clade A gag p24/p17 consensus sequence (pTHr.HIVA) then boosting with a MVA virus expressing HIVA (MVA.HIVA). Phase II clinical trials of the vaccine are underway in Kenya and the UK.
Buscar no Google
Eixos temáticos:
Pesquisa_clinica
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Vacinas contra a AIDS
/
Vacinas de DNA
Limite:
Animals
/
Humans
País como assunto:
Africa
/
Europa
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article